HUSH Restriction in HIV Infected Patients

ANRS, Emerging Infectious Diseases

Status

Unknown

Conditions

HIV Infections

Treatments

Other: Blood sampling

Study type

Observational

Funder types

Other

Identifiers

NCT04172480

ANRS RF 004

Details and patient eligibility

About

HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the "Human Silencing Hub" or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase "SET domain bifurcated 1" (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.

Enrollment

50 estimated patients

Sex

All

Ages

15 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria for group 1:

Symptomatic or asymptomatic acute HIV1 infection
Age above 15 years old
No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure)

Inclusion Criteria for group 2:

Chronic HIV1 infection
Age above 18 years old
No ARV treatment since at least 3 month (regardless the reason)

Inclusion Criteria for group 3:

HIV2 Infection
Age above 18 years old
No ARV treatment since at least 3 month (regardless the reason)

Exclusion Criteria for all groups:

HIV1 and HIV2 co-infection
Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV, tuberculosis, HTLV1)
Life-threatening pathology